Current Report Filing (8-k)
August 04 2021 - 6:00AM
Edgar (US Regulatory)
0001346830
false
0001346830
2021-07-26
2021-07-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 26, 2021
CARA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
|
001-36279
|
|
75-3175693
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
|
|
4 Stamford
Plaza
107 Elm Street, 9th Floor
Stamford, Connecticut
|
|
|
|
06902
|
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
|
|
|
|
|
|
|
Registrant's telephone number, including area code: (203) 406-3700
|
|
|
|
|
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2.):
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common stock, par value $0.001 per share
|
CARA
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
|
|
Item 1.01
|
Entry into a Material Definitive Agreement.
|
On July 26, 2021, Cara Therapeutics, Inc. (“Cara”)
entered into an API Commercial Supply Agreement (the “Agreement”) with Polypeptide Laboratories S.A. (“PPL”) that
defines each party’s responsibilities with respect to PPL’s manufacture and supply of the active pharmaceutical agreement
CR845/difelikefalin (“API”) for the Company’s KORSUVA I.V. product candidate (the “Product Candidate”).
Cara has submitted a new drug application to the U.S. Food and Drug Administration (the “FDA”) with respect to the Product
Candidate for the treatment of moderate-to-severe pruritus in hemodialysis patients.
Under the Agreement, PPL shall manufacture API
at its facility for sale and supply to Cara, in the amounts as set forth in purchase orders to be provided by Cara. Cara will be required
to purchase its requirements of API for each year of the term of the agreement, based on internal forecasts.
The Agreement will continue until the fifth anniversary
of the approval by the FDA of the new drug application for KORSUVA I.V, unless the Agreement is earlier terminated, and will automatically
be extended for successive five year periods unless either party gives notice to the other party of its intention to terminate.
The FDA has conditionally accepted KORSUVA as the
trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been
fully evaluated by any regulatory authority.
The foregoing description of the terms of the Agreement
is only a summary, does not purport to be complete and is qualified in its entirety by reference to the Agreement, which the Company intends
to file as an exhibit to the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2021. Unless otherwise defined
herein, the capitalized terms used above shall have the same meaning ascribed to them in the Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
CARA THERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
/s/ THOMAS REILLY
|
|
|
|
Thomas Reilly
|
|
|
|
Chief Financial Officer
|
|
|
|
(Principal Financial and Accounting Officer)
|
Date: August 3, 2021
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024
